Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae559 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Giorgio Grani und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroglobulin, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
The utility of thyroglobulin (Tg) in the follow-up of patients with differentiated thyroid cancer has been well-documented. Although third-generation immunoassays have improved accuracy, limitations persist (interfering anti-Tg antibodies and measurement variability). Evolving treatment strategies require a reevaluation of Tg thresholds for optimal patient management.
Objective
To assess the performance of serum Tg testing in 2 populations: patients receiving total thyroidectomy and radioiodine remnant ablation (RRA) or treated with thyroidectomy alone.
Design
Prospective observational study.
Setting
Centers contributing to the Italian Thyroid Cancer Observatory database. Patients We included 540 patients with 5 years of follow-up and negative anti-Tg antibodies.
Interventions
Serum Tg levels assessed at 1-year follow-up visit. Main Outcome Measure Detection of structural disease within 5 years of follow-up.
Results
After excluding 26 patients with structural disease detected at any time point, the median Tg did not differ between patients treated with or without radioiodine. Data-driven Tg thresholds were established based on the 97th percentile of Tg levels in disease-free individuals: 1.97 ng/mL for patients undergoing thyroidectomy alone (lower than proposed by the Memorial Sloan Kettering Cancer Center protocol and ESMO Guidelines, yet demonstrating good predictive ability, with a negative predictive value of 98% and 0.84 ng/mL for patients receiving postsurgical RRA. High sensitivity and negative predictive value supported the potential of these thresholds in excluding structural disease.
Conclusion
This real-world study provides evidence for the continued reliability of 1-year serum Tg levels. The data-driven Tg thresholds proposed offer valuable insights for clinical decision-making in patients undergoing total thyroidectomy with or without RRA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy.
- Department of Statistical Sciences, Sapienza University of Rome, 00185 Rome, Italy.
- Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.
- Oncological Endocrinology Unit, Department of Medical Sciences, Città della Salute e della Scienza Hospital, University of Turin, 10126 Turin, Italy.
- Endocrinology and Diabetology Unit, Department of Medicine, Azienda Ospedaliera-Universitaria di Verona, 37126 Verona, Italy.
- Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.
ORCID-Profile: Giorgio Grani, Emanuela Arvat, Maria Chiara Zatelli, Andrea Palermo, Maria Grazia Castagna, Fabio Maino, Clotilde Sparano, Luisa Petrone, Caterina Mian, Giulia Brigante, Umberto Ferraro Petrillo, Sebastiano Filetti, Cosimo Durante
Zitieren
APA
Grani, G., D'Elia, S., Puxeddu, E., Morelli, S., Arvat, E., Nervo, A., Spiazzi, G., Rolli, N., Zatelli, M. C., Ambrosio, M. R., Ceresini, G., Marina, M., Mele, C., Aimaretti, G., Santaguida, M. G., Virili, C., Crescenzi, A., Palermo, A., Rossetto Giaccherino, R., …, & Durante, C. (2025). Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae559
Vancouver
Grani G, D'Elia S, Puxeddu E, Morelli S, Arvat E, Nervo A, et al. Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae559
BibTeX
@article{Grani2025,
author = {Grani, Giorgio and D'Elia, Silvia and Puxeddu, Efisio and Morelli, Silvia and Arvat, Emanuela and Nervo, Alice and Spiazzi, Giovanna and Rolli, Nicoletta and Zatelli, Maria Chiara and Ambrosio, Maria Rosaria and Ceresini, Graziano and Marina, Michela and Mele, Chiara and Aimaretti, Gianluca and Santaguida, Maria Giulia and Virili, Camilla and Crescenzi, Anna and Palermo, Andrea and Rossetto Giaccherino, Ruth and Meomartino, Letizia and Castagna, Maria Grazia and Maino, Fabio and Trevisan, Matteo and De Leo, Simone and Chiofalo, Maria Grazia and Pezzullo, Luciano and Sparano, Clotilde and Petrone, Luisa and Di Dalmazi, Giulia and Napolitano, Giorgio and Tumino, Dario and Crocetti, Umberto and Bertagna, Francesco and Deandrea, Maurilio and Antonelli, Alessandro and Mian, Caterina and Carbone, Antonella and Monti, Salvatore and Porcelli, Tommaso and Brigante, Giulia and Barbaro, Daniele and Alfò, Marco and Ferraro Petrillo, Umberto and Filetti, Sebastiano and Durante, Cosimo},
title = {Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae559}
}
EUVIMED